Seoulin Bioscience Co.,Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021
November 14, 2021 at 10:19 pm EST
Share
Seoulin Bioscience Co.,Ltd. reported earnings results for the third quarter and nine months ended September 30, 2021. For the third quarter, the company reported sales was KRW 48.42 million compared to KRW 92.79 million a year ago. Net income was KRW 13,086.89 million compared to KRW 1,307.98 million a year ago. Basic earnings per share from continuing operations was KRW 1,598.9506 compared to KRW 159.9926 a year ago. Diluted earnings per share from continuing operations was KRW 1,598.9506 compared to KRW 159.9926 a year ago. Basic earnings per share was KRW 1,598.9506 compared to KRW 159.9926 a year ago.
For the nine months, sales was KRW 272.79 million compared to KRW 337.24 million a year ago. Net income was KRW 16,226.37 million compared to KRW 3,406.31 million a year ago. Basic earnings per share from continuing operations was KRW 1,982.3475 compared to KRW 415.5906 a year ago. Diluted earnings per share from continuing operations was KRW 1,982.3475 compared to KRW 415.5906 a year ago. Basic earnings per share was KRW 1,982.3475 compared to KRW 415.5906 a year ago.
Seoulin Bioscience Co., Ltd is a Korea-based company engaged in the developing and manufacturing of basic equipment for bio research. The Company mainly engages in research and development of reagents, such as deoxyribonucleic acid (DNA) chips, which are used for gene therapy, clinical diagnosis, organs transplantation and biopsy; stem cells, which are used for treatment of incurable diseases, Alzheimer disease and others, and next-generation biotechnology drugs. The company supplies its products under the brand name MyLab. It also imports bio research equipment from Thermo Fisher, Affymetrix, Sarstedt and others, and markets in the domestic market. In addition, the Company engages in the real estate rental business.
SEOULIN BIOSCIENCE CO.,LTD. 
